One of the most common points of confusion people run into when applying for CGM or insulin pump coverage is that their diagnosis type matters just as much as their device choice. Insurance coverage criteria, particularly under Medicare, treat type 1 and type 2 diabetes very differently, and those differences can determine whether a device is approved quickly, approved with extra documentation, or denied outright. This guide explains what those differences are, where coverage has expanded in recent years, and what people with type 2 diabetes in particular can do to build the strongest case for approval.
How Coverage Criteria Differ by Diagnosis Type
The CDC notes that CGMs are covered by most private insurance, Medicare, and Medicaid for people with type 1 diabetes, and are also typically covered for people with type 2 diabetes who use insulin or have experienced severe low blood sugar. Insulin pump coverage follows a more restrictive path, particularly under Medicare. Here's a side-by-side overview:
| Coverage Category | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| CGM (Private Insurance) | Broadly covered with prescription | Covered for insulin users; increasingly covered for non-insulin users |
| CGM (Medicare, post-2023) | Covered for all insulin users and documented problematic hypoglycemia | Covered for insulin users; non-insulin users may qualify via hypoglycemia pathway |
| CGM (Medicaid) | Covered in most states, criteria vary | Coverage varies significantly by state; many states still limit to T1D or insulin use |
| Insulin Pump (Private Insurance) | Broadly covered with medical necessity documentation | Covered by many plans with prior authorization; stricter documentation often required |
| Insulin Pump (Medicare) | Covered with insulinopenic or autoantibody documentation | Very limited; most people with T2D do not meet the C-peptide criteria |
CGM Coverage: Where the Lines Fall for Type 1 and Type 2
For CGM coverage, the gap between type 1 and type 2 has narrowed meaningfully in recent years, though it hasn't closed completely.
People with type 1 diabetes have historically been the primary target population for CGM coverage policies, and that remains true today. Under Medicare's 2023 expanded criteria, all beneficiaries with type 1 or type 2 diabetes who use any amount of insulin now qualify for CGM coverage without needing to document a minimum number of daily fingerstick tests. This was a significant simplification from prior rules that required at least three fingerstick tests per day for coverage eligibility.
For people with type 2 diabetes who don't use insulin, coverage is less consistent. Medicare's non-insulin pathway requires documented problematic hypoglycemia, specifically at least two Level 2 hypoglycemic events (glucose below 54 mg/dL) that persisted despite medication adjustments, or a single Level 3 event requiring third-party assistance. Private insurers vary in their approach to non-insulin CGM coverage for type 2 diabetes, and some plans still require insulin use as a baseline criterion.
A research review published in PubMed Central noted that despite growing clinical evidence supporting CGM use for people with type 2 diabetes treated with basal insulin only or even noninsulin therapies, insurance coverage for these populations remains limited or nonexistent in many plans. The ADA actively advocates for broader CGM access across diagnosis types, citing the clinical benefits of continuous monitoring well beyond intensive insulin therapy.
Devices like the Dexcom G7, FreeStyle Libre 3 Plus, and FreeStyle Libre 2 Plus are all approved for both type 1 and type 2 diabetes management, with coverage eligibility determined by your plan's criteria and your prescriber's documentation.
Insulin Pump Coverage: Where the Gap Is Widest
Insulin pump coverage is where the difference between type 1 and type 2 diagnoses is most pronounced, especially under Medicare.
For people with type 1 diabetes, Medicare pump coverage is available through a documented pathway that requires laboratory evidence of being "insulinopenic," typically a low fasting C-peptide level or positive beta-cell autoantibody test, combined with documentation of prior multiple daily injections and frequent blood glucose monitoring. This pathway aligns well with the clinical profile of most people with type 1 diabetes, and while the prior authorization process involves detailed documentation, qualified patients can generally obtain approval.
For people with type 2 diabetes, Medicare's C-peptide requirement presents a significant barrier. People with type 2 diabetes typically retain some degree of endogenous insulin production, meaning their C-peptide levels may not meet the insulinopenic threshold even when they rely heavily on insulin therapy to manage their glucose. A review published in PubMed Central found that current Medicare pump eligibility criteria do not reflect the growing body of clinical evidence supporting pump therapy in people with type 2 diabetes, particularly those on intensive insulin regimens who would benefit significantly from automated delivery.
Under private insurance, the picture for type 2 diabetes is more variable but generally more accessible than Medicare. Many private plans cover insulin pumps for people with type 2 diabetes who are on intensive insulin regimens, with prior authorization based on documentation of medical necessity. If your plan has denied a pump for type 2 diabetes, a letter of medical necessity from your endocrinologist outlining why standard injection therapy is insufficient for your management can sometimes support a successful appeal.
Available insulin pump options through Adapt Health Diabetes for both type 1 and type 2 coverage include the Tandem t:slim X2 with Control-IQ (approved for T1D ages 2+ and T2D adults 18+), the Omnipod 5 (approved for T1D ages 2+ and T2D adults 18+), and the Medtronic MiniMed 780G (approved for T1D ages 7+ and T2D adults 18+).
Why This Distinction Matters and What You Can Do About It
Understanding how your diagnosis type affects your coverage eligibility isn't just useful, it's necessary for building the right case with your insurer and avoiding delays. People with type 1 diabetes who use insulin are generally on the clearest path to CGM and pump coverage under current rules. People with type 2 diabetes on insulin face a more variable landscape depending on their plan and the strength of their provider's documentation. And people with type 2 diabetes who aren't on insulin may face the most friction, even when clinical evidence increasingly supports CGM use for their management. In all cases, working with your endocrinologist to document your clinical need specifically and accurately is the most important factor. At Adapt Health Diabetes, our team can help verify your specific coverage and identify what documentation your insurer requires before your order is placed. Visit our Learning Center for more resources on coverage and device access.
Frequently Asked Questions About Coverage Differences by Diabetes Type
I have type 2 diabetes and don't use insulin. Can I still get a CGM covered?
Possibly, but it depends on your insurance plan. Under Medicare, the non-insulin pathway requires documented problematic hypoglycemia meeting specific clinical criteria. Under private insurance, some plans now cover CGMs for people with type 2 diabetes regardless of insulin use, while others still require it. Your provider can help document the clinical rationale for CGM use in your specific case, and your DME supplier can verify your plan's current criteria before ordering. Coverage for non-insulin type 2 patients is an area of active expansion, so it's worth checking even if you've been told no in the past.
Does having type 2 diabetes mean I can't get an insulin pump covered?
Under Medicare, coverage for people with type 2 diabetes is very limited due to the C-peptide eligibility requirement, which most people with type 2 diabetes cannot meet. Under private insurance, coverage is more variable and many plans do cover pumps for people with type 2 diabetes on intensive insulin therapy with appropriate prior authorization. If your private plan has denied coverage, an appeal supported by a detailed letter of medical necessity from your endocrinologist is worth pursuing. Speak with your provider and your DME supplier to understand your specific options.
Will my coverage change if my diagnosis is reclassified from type 2 to type 1 (or LADA)?
Yes, potentially significantly. People who are reclassified as having type 1 diabetes or Latent Autoimmune Diabetes in Adults (LADA) may become eligible for coverage pathways that weren't available to them under a type 2 classification, including Medicare pump coverage via the autoantibody positivity criterion. If your clinical presentation has changed or your provider suspects LADA based on your response to treatment or laboratory findings, it's worth discussing reclassification and how it might affect your device coverage options.
Is Medicaid coverage for CGMs and pumps the same across all states?
No. Medicaid is administered at the state level, which means coverage criteria vary significantly. Some states cover CGMs for both type 1 and insulin-using type 2 patients. Others limit coverage to type 1 diabetes only, or require a minimum number of daily fingerstick tests. Pump coverage under Medicaid is similarly variable. If you're on Medicaid and interested in a CGM or pump, contacting your state Medicaid agency or working with a DME supplier familiar with your state's policies is the best first step.
If I'm covered for a CGM, am I automatically covered for an insulin pump too?
No. CGM coverage and insulin pump coverage are evaluated separately, each with their own eligibility criteria and prior authorization processes. Being approved for a CGM does not automatically qualify you for a pump, and vice versa. That said, having an approved CGM already on file can strengthen your pump application by demonstrating that your glucose management requires close monitoring. Your provider can address both requests in your documentation to give each the strongest possible case.
Not Sure What's Covered Under Your Plan? We Can Help.
Adapt Health Diabetes verifies your insurance coverage before any order ships, so you know exactly what you're approved for and what you'll owe. Whether you have type 1 or type 2 diabetes, our team works with your provider and insurer to ensure you're getting every benefit you qualify for. Explore our full range of Dexcom and Abbott FreeStyle CGMs and insulin pump options, or visit our Resources page for additional information. Contact our team to get started.
This article is for educational purposes only and does not replace professional medical or financial advice. Coverage policies are subject to change. Always verify current eligibility requirements with your insurance provider and healthcare team.
Sources
- Centers for Disease Control and Prevention. Continuous Glucose Monitors. CDC Diabetes. Updated November 2025.
- American Diabetes Association. Continuous Glucose Monitoring: Benefits, Accessibility and How It Works. ADA.
- Aleppo G, et al. Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies. PubMed Central. 2023.
- Kerr D, et al. Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion. PubMed Central. 2021.
